Aimée R. Kreimer | |
---|---|
Born | Aimée Rebecca Kreimer August 19, 1975
Washington, D.C., U.S. |
Alma mater |
University of Delaware University of Virginia Johns Hopkins Bloomberg School of Public Health |
Scientific career | |
Fields | Cancer epidemiology, HPV, cancer prevention |
Institutions | National Cancer Institute |
Aimée Rebecca Kreimer (born August 19, 1975) is an American cancer epidemiologist who researches the etiology and prevention of human papillomavirus infection (HPV) and cancer prevention. She is a senior investigator in the infections and immunoepidemiology branch at the National Cancer Institute.
Kreimer was born August 19, 1975, in Washington, D.C. [1] She completed a B.S. in Animal Science with a minor in Biology and a concentration in pre-veterinary medicine at the University of Delaware in May 1997. [1] Kreimer earned a M.S. from the department of health evaluation sciences, division of biostatistics and epidemiology at the University of Virginia in May 1998. [1] Her thesis was titled, Evaluation of the Effectiveness of Treatment with Cortisol in Physiologic Doses in Patients with Naturally Acquired Influenza A. [1] Kreimer received a Ph.D. in infectious disease epidemiology from the Johns Hopkins Bloomberg School of Public Health. [2] Her 2003 dissertation was titled, The descriptive epidemiology of oral human papilloma virus (HPV) infection: associations with high-risk sexual behaviors and HPV serostatus. [1] Anthony J. Alberg was her doctoral advisor and Maura L. Gillison was her mentor. [1] Kreimer conducted postdoctoral research at the International Agency for Research on Cancer and the National Cancer Institute (NCI). [2]
Kreimer is a senior investigator in the NCI infections and immunoepidemiology branch (IIB). [2] She studies the etiology and prevention of human papillomavirus (HPV) and cancers at multiple sites, including the head and neck and anogenital region, with a particular focus on translational research and cancer prevention. [2] In 2018, she received the National Institutes of Health (NIH) Director's Award in the category of Science/Medicine for her outstanding achievements in HPV cancer research and leadership in the Costa Rica HPV Vaccine Trial. [2] In 2021, she was elected by her peers to serve a three-year term as NCI division of cancer epidemiology and genetics (DCEG) Woman Scientific Advisor, and elected to the executive board of the International Papillomavirus Society. [2]